Cargando…
VAX014, an Oncolytic Therapy, Reduces Adenomas and Modifies Colon Microenvironment in Mouse Model of CRC
Colorectal cancer (CRC) remains the third most common form of cancer and, despite its reduced mortality, results in over 50,000 deaths annually, highlighting the need for novel therapeutic approaches. VAX014 is a novel clinical-stage, oncolytic bacterial minicell-based therapy shown to elicit protec...
Autores principales: | Grenier, Shea F., Khan, Mohammad W., Reil, Katherine A., Sawaged, Savannah, Tsuji, Shingo, Giacalone, Matthew J., Tian, Mengxi, McGuire, Kathleen L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298379/ https://www.ncbi.nlm.nih.gov/pubmed/37373142 http://dx.doi.org/10.3390/ijms24129993 |
Ejemplares similares
-
Intravesical VAX014 Synergizes with PD-L1 Blockade to Enhance Local and Systemic Control of Bladder Cancer
por: Tsuji, Shingo, et al.
Publicado: (2022) -
Intralesional administration of VAX014 facilitates in situ immunization and potentiates immune checkpoint blockade in immunologically cold tumors
por: Reil, Katherine A, et al.
Publicado: (2023) -
Preclinical evaluation of VAX-IP, a novel bacterial minicell-based biopharmaceutical for nonmuscle invasive bladder cancer
por: Tsuji, Shingo, et al.
Publicado: (2016) -
Magnetic Field Effects on the Structure, Dielectric and Energy Storage Properties of High-Entropy Spinel Ferrite (La(0.14)Ce(0.14)Mn(0.14)Zr(0.14)Cu(0.14)Ca(0.14)Ni(0.14))Fe(2)O(4)/PVDF Nanocomposites
por: Qiao, Jiale, et al.
Publicado: (2023) -
HealVax
por: Foerster, John, et al.
Publicado: (2018)